Mark Duquette

2.9k total citations
37 papers, 2.1k citations indexed

About

Mark Duquette is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Mark Duquette has authored 37 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 17 papers in Cancer Research and 8 papers in Oncology. Recurrent topics in Mark Duquette's work include Angiogenesis and VEGF in Cancer (23 papers), Protease and Inhibitor Mechanisms (13 papers) and Cell Adhesion Molecules Research (6 papers). Mark Duquette is often cited by papers focused on Angiogenesis and VEGF in Cancer (23 papers), Protease and Inhibitor Mechanisms (13 papers) and Cell Adhesion Molecules Research (6 papers). Mark Duquette collaborates with scholars based in United States, Israel and United Kingdom. Mark Duquette's co-authors include Jack Lawler, Richard O. Hynes, Kemin Tan, A. Joachimiak, Helen Rayburn, Valérie Thibert, Elizabeth George, Mary E. Sunday, Jia‐Huai Wang and Jin‐huan Liu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Mark Duquette

36 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Duquette United States 25 1.4k 496 359 347 271 37 2.1k
Martin Hagedorn France 28 1.5k 1.0× 468 0.9× 442 1.2× 250 0.7× 221 0.8× 42 2.2k
William E. Allen United Kingdom 16 1.4k 1.0× 552 1.1× 289 0.8× 588 1.7× 397 1.5× 26 2.4k
Paul Hiscott United Kingdom 37 1.5k 1.0× 257 0.5× 449 1.3× 290 0.8× 284 1.0× 122 4.2k
Shawn M. Ellerbroek United States 20 1.3k 0.9× 613 1.2× 522 1.5× 596 1.7× 183 0.7× 26 2.3k
Pierre Roux France 27 1.6k 1.1× 332 0.7× 656 1.8× 454 1.3× 179 0.7× 49 2.4k
Reed Hickey United States 17 1.6k 1.1× 483 1.0× 311 0.9× 289 0.8× 180 0.7× 19 2.7k
Sally E. Stringer United Kingdom 21 1.5k 1.0× 335 0.7× 248 0.7× 951 2.7× 187 0.7× 25 2.3k
Miller Huang United States 21 1.9k 1.3× 690 1.4× 483 1.3× 318 0.9× 304 1.1× 30 2.9k
Taly R. Spivak-Kroizman United States 14 1.9k 1.3× 704 1.4× 446 1.2× 621 1.8× 246 0.9× 17 2.6k
Håkan Hedman Sweden 28 1.5k 1.0× 328 0.7× 601 1.7× 190 0.5× 493 1.8× 71 2.3k

Countries citing papers authored by Mark Duquette

Since Specialization
Citations

This map shows the geographic impact of Mark Duquette's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Duquette with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Duquette more than expected).

Fields of papers citing papers by Mark Duquette

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Duquette. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Duquette. The network helps show where Mark Duquette may publish in the future.

Co-authorship network of co-authors of Mark Duquette

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Duquette. A scholar is included among the top collaborators of Mark Duquette based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Duquette. Mark Duquette is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lee, Somin, Zohreh Amoozgar, Sonu Subudhi, et al.. (2025). Wnt inhibition alleviates resistance to anti-PD1 therapy and improves antitumor immunity in glioblastoma. Proceedings of the National Academy of Sciences. 122(38). e2414941122–e2414941122.
2.
Dong, Xinyue, Jun Ren, Zohreh Amoozgar, et al.. (2023). Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice. Journal for ImmunoTherapy of Cancer. 11(3). e005583–e005583. 79 indexed citations
3.
Duquette, Mark, et al.. (2014). Thrombospondin-1 Modulates Actin Filament Remodeling and Cell Motility in Mouse Mammary Tumor cells in Vitro. PubMed. 2(4). e31–e31. 13 indexed citations
4.
Duquette, Mark, Monica J. S. Nadler, Dayne Okuhara, et al.. (2014). Members of the thrombospondin gene family bind stromal interaction molecule 1 and regulate calcium channel activity. Matrix Biology. 37. 15–24. 28 indexed citations
5.
6.
7.
Johnson, Candice, Tatiana Cárdenas, Siddharth Pratap, et al.. (2012). Thrombospondin-1 Interacts with Trypanosoma cruzi Surface Calreticulin to Enhance Cellular Infection. PLoS ONE. 7(7). e40614–e40614. 22 indexed citations
8.
Ren, Bin, Keli Song, Sareh Parangi, et al.. (2009). A Double Hit to Kill Tumor and Endothelial Cells by TRAIL and Antiangiogenic 3TSR. Cancer Research. 69(9). 3856–3865. 44 indexed citations
9.
Tan, Kemin, Mark Duquette, Jin‐huan Liu, Jack Lawler, & Jia‐Huai Wang. (2008). The Crystal Structure of the Heparin-Binding Reelin-N Domain of F-Spondin. Journal of Molecular Biology. 381(5). 1213–1223. 19 indexed citations
10.
Yee, Karen O., et al.. (2008). The effect of thrombospondin-1 on breast cancer metastasis. Breast Cancer Research and Treatment. 114(1). 85–96. 107 indexed citations
11.
Tan, Kemin, Mark Duquette, Jin‐huan Liu, et al.. (2007). Heparin-induced cis- and trans-Dimerization Modes of the Thrombospondin-1 N-terminal Domain. Journal of Biological Chemistry. 283(7). 3932–3941. 29 indexed citations
12.
Tan, Kemin, Mark Duquette, Jin‐huan Liu, et al.. (2006). The Structures of the Thrombospondin-1 N-Terminal Domain and Its Complex with a Synthetic Pentameric Heparin. Structure. 14(1). 33–42. 73 indexed citations
13.
14.
Zhang, Xuefeng, et al.. (2005). Antiangiogenic Treatment with the Three Thrombospondin-1 Type 1 Repeats Recombinant Protein in an Orthotopic Human Pancreatic Cancer Model. Clinical Cancer Research. 11(6). 2337–2344. 24 indexed citations
15.
Zhang, Xuefeng, et al.. (2005). Antiangiogenic Treatment with Three Thrombospondin-1 Type 1 Repeats versus Gemcitabine in an Orthotopic Human Pancreatic Cancer Model. Clinical Cancer Research. 11(15). 5622–5630. 28 indexed citations
16.
Lawler, Jack, Weimin Miao, Mark Duquette, et al.. (2001). Thrombospondin-1 Gene Expression Affects Survival and Tumor Spectrum of p53-Deficient Mice. American Journal Of Pathology. 159(5). 1949–1956. 89 indexed citations
17.
Urry, Lisa A., Charles A. Whittaker, Mark Duquette, Jack Lawler, & Douglas W. DeSimone. (1998). Thrombospondins in earlyXenopus embryos: Dynamic patterns of expression suggest diverse roles in nervous system, notochord, and muscle development. Developmental Dynamics. 211(4). 390–407. 29 indexed citations
18.
Lawler, Jack, Mary E. Sunday, Valérie Thibert, et al.. (1998). Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia.. Journal of Clinical Investigation. 101(5). 982–992. 374 indexed citations
19.
Lawler, Jack, et al.. (1993). Identification and characterization of thrombospondin-4, a new member of the thrombospondin gene family.. The Journal of Cell Biology. 120(4). 1059–1067. 124 indexed citations
20.
Lawler, Jack, et al.. (1993). The evolution of the thrombospondin gene family. Journal of Molecular Evolution. 36(6). 509–516. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martin Hagedorn Breakdown of academic impact, for papers by William E. Allen Breakdown of academic impact, for papers by Paul Hiscott Breakdown of academic impact, for papers by Shawn M. Ellerbroek Breakdown of academic impact, for papers by Pierre Roux Breakdown of academic impact, for papers by Reed Hickey Breakdown of academic impact, for papers by Sally E. Stringer Breakdown of academic impact, for papers by Miller Huang Breakdown of academic impact, for papers by Taly R. Spivak-Kroizman Breakdown of academic impact, for papers by Håkan Hedman
Rankless by CCL
2026